ArticleCureus2025
Long-Term Outcomes of Simultaneous Integrated Boost in Node-Positive Cervical Cancer: A Single-Institution Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Nodal involvement in cervical cancer is associated with poor prognosis. Although modern radiotherapy techniques (intensity-modulated radiotherapy (IMRT)/volumetric-modulated arc therapy (VMAT)) enable safe nodal dose escalation, clinical data, particularly from Indian settings and node-positive subgroups, remain limited. This study evaluated outcomes and toxicity using a simultaneous integrated boost (SIB) to radiologically involved nodes. Methods We retrospectively analyzed 56 patients with node-positive, locally advanced cervical cancer treated between 2018 and 2023. All patients received pelvic external-beam radiotherapy (45-50 Gy) with nodal SIB (median, 55 Gy in 25 fractions), followed by intracavitary brachytherapy (24 Gy in 3 fractions or 28 Gy in 4 fractions). Weekly cisplatin was administered when feasible. Tumor and nodal responses were assessed at 3 months, and survival was estimated using Kaplan-Meier and compared with log-rank tests. Results After a median follow-up period of 35 months, complete response was observed in 46 (81.8%) and 51 (91%) patients with primary and nodal diseases, respectively. Initial failures were categorized as local in seven cases (12.5%), regional in six (10.7%), and distant in 15 (27.3%). The five-year local and regional control rates were 86% and 85%, respectively; the distant recurrence-free survival rate was 64%, and the overall survival rate was 68%. Patients with para-aortic nodal disease (IIIC2) exhibited inferior distant control compared to those with IIIC1 (median, 29 months vs. not reached; p = 0.047). Late grade ≥3 gastrointestinal and genitourinary toxicities were observed in two (3.6%) and one (1.8%) patients, respectively. Vaginal stenosis was reported in 14 (25.0%) patients, with grade 3 stenosis occurring in 2 (3.6%) patients. Conclusions Definitive chemoradiation with IMRT/VMAT using a simultaneous integrated nodal boost achieved high complete response rates, excellent pelvic control, and low rates of severe late toxicity in node-positive cervical cancer. Distant relapse remained the main pattern of failure, particularly in patients with para-aortic involvement. These findings support nodal dose escalation as a safe, practical strategy and highlight the need for systemic intensification in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.